Showing results (231-240 of 296) with videos related to
Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapyHarold J Burstein, Yu-Hui Chen, Leroy M Parker, et al.Oncotarget|January 19, 2013
Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibitionPooja Mohan, Joan Castellsague, Jihong Jiang, et al.International Journal of Neonatal Screening|June 2, 2021
Massachusetts' Findings from Statewide Newborn Screening for Spinal Muscular AtrophyJaime E Hale, Basil T Darras, Kathryn J Swoboda, et al.Science Translational Medicine|May 7, 2025
Patient-derived models of UBA5-associated encephalopathy identify defects in neurodevelopment and highlight potential therapeutic avenuesHelen Chen, Christy W LaFlamme, Yong-Dong Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2017
Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518James C Yao, Katherine A Guthrie, Cesar Moran, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2014
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium ReportMaryam Fouladi, John P Perentesis, Lars M Wagner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkersJoseph Baar, Paula Silverman, Janice Lyons, et al.Pediatric Blood & Cancer|April 6, 2011
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology GroupMartin A Champagne, Cecilia H Fu, Myron Chang, et al.Development and Psychopathology|March 27, 2026
Maternal mood entropy and children's hippocampal development: Enduring versus transient effectsKatherine E Jennings, Daniela G Juarez, Jessica P Uy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2008
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinomaAbby B Siegel, Emil I Cohen, Allyson Ocean, et al.Pageof 30